Six unapproved peptides will become legally sellable at specialized pharmacies under a Department of Health and Human Services policy dated Oct. 29, 2026. The policy, driven by HHS Secretary Robert F. Kennedy Jr., expands access to BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 — none of which has been approved by the U.S. Food and Drug Administration.

The stakes are commercial as much as medical. Until now, consumers could buy these substances only through a gray market of online sellers and wellness stores exploiting legal loopholes. The new policy moves the products into licensed compounding pharmacies (facilities permitted to produce small sets of drugs not reviewed by the FDA), with no regulator checking their safety, efficacy or contents.

What does the policy change?

Peptides are short chains of amino acids, the building blocks of proteins. More than 7,000 occur naturally in the human body. Some have become legitimate medicines — insulin is the classic example, and GLP-1 drugs such as Ozempic and Wegovy are peptide-based. Those products passed clinical trials and FDA approval.

The six peptides in the new policy took a different route. American consumers have been able to buy wellness peptides online for over a decade. Some specialized pharmacies also sold them until 2023, when the FDA restricted access to several, citing unnamed "significant safety concerns" and forbidding pharmacies from compounding them. Online sales continued regardless.

Kennedy reversed that course. Earlier in 2026 he pushed the FDA to review the peptides restricted in 2023, and he appointed eight new members to the committee advising the agency on compounding matters — all eight, according to reporting by STAT, had ties to businesses selling or promoting peptides. In July 2026 the committee voted 8-6 to expand access to the six substances.

The vote came after FDA scientists repeatedly told the committee that there was not enough information on the peptides' safety and efficacy to justify letting compounding pharmacies sell them.

Why are these products popular?

Social media has amplified demand, driven by the MAHA (Make America Healthy Again) movement since the early 2020s. Influencers market the combination of BPC-157 and TB-500 as the "Wolverine stack," named after the Marvel superhero, recommending it for muscle growth and postworkout recovery. Kennedy has promoted the peptides in podcasts and through his Take Back Your Health tour.

How does enforcement discretion work?

The policy relies on a tool known as enforcement discretion: the law gives an agency authority to regulate, and the agency chooses not to use it, typically when it judges a product low-risk. Observers often describe it as the regulator "looking the other way." The FDA used the same tool during a recent shortage of weight-loss drugs, letting compounding pharmacies produce them to ease supply.

The precedent for what can go wrong is documented. The FDA long exercised enforcement discretion over laboratory-developed tests, including tests for Lyme disease and breast and ovarian cancer. Genomic Health began selling a breast cancer screening test in 2008; scientists questioned its accuracy in 2011, and in 2014 the test was confirmed to have delivered false negatives to cancer patients. Theranos's blood tests fell into the same unregulated category, which helped Elizabeth Holmes conceal her fraud for years.

Who checks what is in the vials?

Kennedy and other proponents argue that pharmacy-channel sales are safer than online purchases because pharmacists provide oversight. The new policy's wording echoes that sentiment. The claim does not hold up structurally: compounding pharmacies have no obligation to test any ingredients they obtain from outside suppliers.

Federal law requires the FDA to evaluate drugs before sale and monitor their production; those requirements do not apply to compounded drugs. The FDA's own website warns that the lack of regulation opens the door to "poor compounding practices" and that some compounded products can be unsafe or ineffective.

What are the longer-term consequences?

The decision may also reshape commercial research incentives. FDA law rewards companies for studying their products, because approval requires evidence. By signaling that peptides can reach consumers without study, the agency removes that incentive, according to Ana Santos Rutschman, a health law professor at Villanova University who researches FDA law and policy. In her view, the policy may discourage research into the peptides, including work that could uncover novel applications.

The immediate arithmetic for consumers is simple: more places will sell these six peptides, and no regulator will verify what is in them.